Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 11

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 11
---
, upon written request directed to the Corporate Secretary, IMUNON, INC., 997 Lenox Drive, Suite 100, Lawrenceville, New Jersey 08648.

Householding of Annual Meeting Materials

Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of our Proxy Statement or 2024 annual report to stockholders may have been sent to multiple stockholders in your household. The Company will promptly deliver a separate copy of either document to you if you write or call the Company at the following address or telephone number:

<div align='center'>IMUNON, INC.

997 Lenox Drive

Suite 100

Lawrenceville, New Jersey 08648

Attention: Corporate Secretary

(609) 896-9100</div>

If you would like to receive separate copies of the proxy materials in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact the Company at the address and telephone number set forth above.

PLEASE COMPLETE, SIGN, DATE AND RETURN THE ACCOMPANYING WHITE PROXY CARD IN THE ENCLOSED PRE-ADDRESSED AND POSTAGE-PAID ENVELOPE AS PROMPTLY AS POSSIBLE OR SUBMIT YOUR VOTE VIA THE INTERNET AT WWW.PROXYVOTE.COMOR BY CALLING THE NUMBER PRINTED ON THE ACCOMPANYING PROXY CARD.

| 9 |

<div align='center'>BENEFICIAL OWNERSHIP OF COMMON STOCK</div>

The following table is furnished by the Company and sets forth certain information known to the Company regarding the beneficial ownership of the Company’s common stock as of May 13, 2025 by:

| ● | each                                                                                                                                  
 person or group known by us to own beneficially more than 5% of the Company’s outstanding common stock;                               |
| ● | each                                                                                                                                  
 of our directors and the director nominees, as well as each executive officer named in the Summary Compensation Table appearing under 
 the heading “Executive Compensation;” and                                                                                             |
| ● | our                                                                                                                                   
 directors and executive officers as a group.                                                                                          |

We determine beneficial ownership in accordance with the rules of the SEC. Under SEC rules, beneficial ownership for purposes of this table takes into account shares as to which the individual has voting or investment power (including shares held indirectly through the Imunon